Virscio Announces Hiring of Sven Korte, Ph.D. as Senior Director of Research and Safety Assessment

An industry veteran, Dr. Korte will enable Virscio to continue to expand scientific impact on Sponsor programs by de-risking clinical development, while accelerating adoption of alternative models for regulatory toxicology.

NEW HAVEN, Conn. & ST. KITTS, West Indies–(BUSINESS WIRE)–Virscio, a leading provider of translational research and development services, has announced the appointment of Sven Korte, Ph.D. and board-certified toxicologist, as Senior Director of Research and Safety Assessment.

Dr. Korte’s appointment comes at a time of expanding demand for translational research capabilities to address the accelerating needs of precision medicine and novel therapeutic modalities. His scientific leadership and deep expertise in preclinical and safety toxicology will further enable Virscio’s support of Sponsor programs amid ongoing industry-wide shortages in access to robust translational models.

Prior to joining Virscio, Dr. Korte spent 25 years as a Senior Study Director LabCorp’s Early Development Services group, based in Münster, Germany. During his long tenure, Dr. Korte oversaw sponsor engagement and study execution of more than 220 studies and has become a globally recognized key opinion leader in preclinical safety assessment across a wide range of therapeutic modalities, with extensive expertise in antisense oligonucleotides and gene therapy products using nonhuman primates (NHP).

“It is a privilege to welcome Dr. Korte to our team,” Dr. Matthew Lawrence, Chief Executive Officer of Virscio, said. “Sven’s deep expertise and passion for translational research aligns perfectly with our mission to accelerate the delivery of high-quality, safe, and effective therapeutics to patients worldwide.”

Over the course of his distinguished scientific career, Dr. Korte has participated in more than 110 professional publications and lectured at numerous research symposiums and congresses across the globe. In addition, Dr. Korte has contributed to several books on the role of NHPs in drug development and was the co-editor of “The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment”. Dr. Korte earned a Ph.D. in Zoology from the University of Kassel in Kassel, Germany in 1998.

“I am honored to join Virscio and contribute to its pioneering work in drug discovery and development,” Dr. Korte said. “I believe that Virscio’s multidisciplinary approach, cutting-edge technologies, and strong focus on safety assessment position it at the forefront of the industry. I am excited to collaborate with the talented team at Virscio and make a meaningful impact in advancing healthcare through innovative therapies.”

About Virscio: Virscio is a specialty translational research organization developing and providing innovative preclinical and translational research services, in vivo nonhuman primate disease modeling, and related preclinical and histopathology services to meet the preclinical, translational, and regulatory research needs of the life sciences, biotechnology, and pharmaceutical industries. Virscio specializes in non-GLP and GLP in vivo study design, execution, and sample, data, and image analysis to enable rapid translation of preclinical therapeutic candidates from early proof of concept to IND-enabling studies, leveraging unique and significant access to nonhuman primates and integrated therapeutic domain expertise and capabilities.

For more information, please visit www.virscio.com.

Contacts

For media inquiries, please contact:
Christopher Stanley,

Chief Business Officer

[email protected]